Semaglutide Improves Cognitive Function in People with Depression and Obesity | Research

The takeaway

A randomized clinical trial found semaglutide improved cognitive dysfunction in overweight/obese adults with major depressive disorder over 16 weeks.

First RCT evidence
Semaglutide improved cognitive dysfunction in depressed, overweight/obese adults over 16 weeks

What the researchers found

Semaglutide significantly improved cognitive dysfunction in overweight/obese adults with major depressive disorder in a 16-week randomized clinical trial.

Why it matters

This is landmark evidence — the first RCT showing a GLP-1 RA improves cognition in depression. Cognitive dysfunction is one of the most disabling aspects of depression and lacks targeted treatments.

How the study worked

16-week randomized, double-blind, placebo-controlled, parallel-group trial (NCT04466345); overweight/obese adults with DSM-5 MDD and cognitive impairment.

What this study cannot tell us

Participants were overweight/obese — unclear if cognitive benefits extend to normal-weight depression patients; relatively short 16-week duration; adjunctive therapy (added to existing treatment).

How to read the evidence

Randomized, double-blind, placebo-controlled trial — the gold standard for clinical evidence. Published in Med (Cell Press).

When this study was published

Published 2026 in Med. Trial registration: NCT04466345.

The bigger picture

If GLP-1 RAs can treat cognitive dysfunction in depression, they could become a novel class of cognitive enhancers for psychiatric conditions — a completely new therapeutic application.

Questions still open

Is the cognitive benefit driven by metabolic improvement, direct brain effects, or both?
Will longer treatment maintain or enhance cognitive improvements?

Common questions

Can semaglutide help with depression-related brain fog?

This clinical trial showed semaglutide improved cognitive function in people with depression and obesity — the first evidence from a randomized trial that GLP-1 drugs may help with depression-related cognitive problems.

Does this mean semaglutide is an antidepressant?

The study focused on cognitive dysfunction, not depression symptoms overall. While the cognitive improvement is significant, semaglutide was used as an add-on to existing depression treatment, not as a standalone antidepressant.

Read the original research

Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.

Med (New York, N.Y.), 7(1), 100916

View on PubMed ↗Publisher’s paper ↗

Citation

Badulescu, Sebastian; Gill, Hartej; Shah, Hiya; Brudner, Ryan; Phan, Lee; Di Vincenzo, Joshua D; Tabassum, Aniqa; Armanyous, Michael; Llach, Cristian-Daniel; Rosenblat, Joshua D; McIntyre, Roger S; Mansur, Rodrigo B. (2026). Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.. Med (New York, N.Y.), 7(1), 100916. https://doi.org/10.1016/j.medj.2025.100916